Risk Factors for Perinatal Transmission of Human Immunodeficiency Virus Type 1 in Women Treated with Zidovudine
Lynne Mofenson(Elizabeth Glaser Pediatric AIDS Foundation), George J. Nemo(National Heart Lung and Blood Institute), Jean Whitehouse(Westat (United States)), John S. Lambert(Mater Misericordiae University Hospital), D.R. Harris(Westat (United States)), William A. Meyer(Quest Diagnostics (United States)), E. Richard Stiehm(European Respiratory Society), Jack Moye(National Institutes of Health), Patricia Reichelderfer(Health and Human Development (2HD) Research Network), Mary Glenn Fowler(Johns Hopkins University), Bonnie J. Mathieson(National Institute of Allergy and Infectious Diseases), James Bethel(Westat (United States))
Cited by 553
Related Papers
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
|New England Journal of Medicine|1994|3.7k
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
|The Lancet|1999|1.7k
Liberal or Restrictive Transfusion in High-Risk Patients after Hip Surgery
|New England Journal of Medicine|2011|1.3k
Combination Antiretroviral Strategies for the Treatment of Pregnant HIV-1–Infected Women and Prevention of Perinatal HIV-1 Transmission
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2002|896